Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature

Atherosclerosis

Volumn 247, Issue , 2016, Pages 189-192

  Kołodziejczak, Michalina ^a,b   Navarese, Eliano P ^a,c  

^a Research on Interventions and Outcomes (SIRIO) MEDICINE Research Network   (Germany)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Meta analysis; Mortality; Neurocognitive effects; PCSK9 antibodies

Indexed keywords

ALIROCUMAB; CHOLESTEROL; EVOLOCUMAB; EZETIMIBE; MONOCLONAL ANTIBODY; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 ANTIBODY; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; LIPID; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DEMENTIA; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; META ANALYSIS; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG EFFECTS; DYSLIPIDEMIAS; ENZYMOLOGY; EVIDENCE BASED MEDICINE; IMMUNOLOGY; MORTALITY; NEUROCOGNITIVE DISORDERS; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR;

ANTIBODIES, MONOCLONAL; BIOMARKERS; CARDIOVASCULAR DISEASES; COGNITION; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; NEUROCOGNITIVE DISORDERS; PROPROTEIN CONVERTASE 9; RISK ASSESSMENT; RISK FACTORS;

EID: 84959143343     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.02.011     Document Type: Review

References (12)

1. Nabel E.G., Braunwald E. A tale of coronary artery disease and myocardial infarction. N. Engl. J Med. 2012, 366:54-63.
2. Navarese E.P., Kolodziejczak M., Dimitroulis D., et al. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. Eur. Heart J. Cardiovasc Pharmacother. 2015, pvv045, [ahead of print].
3. Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015, 372:2387-2397.
4. Navarese E.P., Kolodziejczak M., Schulze V., et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann. Intern Med. 2015, 163:40-51.
5. Califf R.M. Issues facing clinical trials of the future. J. Intern Med. 2003, 254:426-433.
6. Lipinski M.J., Benedetto U., Escarcega R.O., et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur. Heart J. 2016 Feb 7, 37(6):536-545.
7. Sabatine M.S., Giugliano R.P., Wiviott S.D., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 2015 Apr 16, 372(16):1500-1509.
8. Hozo I., Djulbegovic B., Clark O., Lyman G.H. Use of re-randomized data in meta-analysis. BMC Med. Res. Methodol. 2005, 5:17.
9. Food and Drug Administration Briefing Document The Endocrinologic and Metabolic Drugs Advisory Committee Meeting June 10, 2015, Repatha (evolocumab) injections. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM450072.pdf.
10. Food and Drug Administration Briefing Document The Endocrinologic and Metabolic Drugs Advisory Committee Meeting June 9, 2015, Pralutent (alirocumab) injection. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM449865.pdf.
11. Evaluating PCSK9 Binding AntiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS). https://clinicaltrials.gov/ct2/show/NCT02207634.
12. Navarese E.P., Kołodziejczak M., Kereiakaes D.J. Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome. A narrative review. Ann. Intern Med. 2016, [in press, Epub ahead of print].